Previous close | 395.99 |
Open | N/A |
Bid | 451.00 |
Ask | 459.30 |
Strike | 190.00 |
Expiry date | 2024-06-21 |
Day's range | 395.99 - 395.99 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatid
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?